Vertex Pharmaceuticals Incorporated (ETR:VX1)
Germany · Delayed Price · Currency is EUR 352.35
-8.65 (-2.40%)
Nov 7, 2025, 5:35 PM CET
Vertex Pharmaceuticals Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Net Income | 3,675 | -535.6 | 3,620 | 3,322 | 2,342 | 2,712 | Upgrade |
Depreciation & Amortization | 175.4 | 182 | 169.5 | 148.3 | 125.6 | 109.5 | Upgrade |
Other Amortization | 25.2 | 25.2 | 11.8 | - | - | - | Upgrade |
Asset Writedown & Restructuring Costs | 379 | - | - | - | - | - | Upgrade |
Loss (Gain) From Sale of Investments | 19.4 | 57.7 | 0.6 | 149.1 | -17.1 | -311.9 | Upgrade |
Stock-Based Compensation | 696.1 | 698.5 | 581.2 | 491.3 | 441.4 | 429.5 | Upgrade |
Other Operating Activities | -440.7 | -405.6 | -579.7 | -321.6 | -143.3 | 369.1 | Upgrade |
Change in Accounts Receivable | -178.9 | -99.3 | -84.1 | -358.6 | -274.7 | -223.4 | Upgrade |
Change in Inventory | -594.3 | -517.3 | -322.9 | -136.4 | -92.8 | -132 | Upgrade |
Change in Accounts Payable | 6.9 | 49.5 | 48.7 | 120.8 | 31.9 | 51.3 | Upgrade |
Change in Other Net Operating Assets | -45.2 | 52.3 | 92.6 | 715 | 230.4 | 249.7 | Upgrade |
Operating Cash Flow | 3,718 | -492.6 | 3,537 | 4,130 | 2,644 | 3,254 | Upgrade |
Operating Cash Flow Growth | - | - | -14.35% | 56.23% | -18.75% | 107.32% | Upgrade |
Capital Expenditures | -380.8 | -297.7 | -200.4 | -204.7 | -235 | -259.8 | Upgrade |
Cash Acquisitions | - | - | - | -295.9 | - | - | Upgrade |
Sale (Purchase) of Intangibles | - | -187.7 | -58 | - | - | - | Upgrade |
Investment in Securities | -1,059 | -3,231 | -2,852 | 227.3 | -105.9 | 359.2 | Upgrade |
Other Investing Activities | -39.7 | -54 | -31 | -47.8 | - | - | Upgrade |
Investing Cash Flow | -1,479 | -3,770 | -3,142 | -321.1 | -340.9 | 99.4 | Upgrade |
Long-Term Debt Issued | - | - | - | - | 28.3 | 13.3 | Upgrade |
Total Debt Issued | - | - | - | - | 28.3 | 13.3 | Upgrade |
Long-Term Debt Repaid | - | -33.6 | -44.9 | -85.5 | -47 | -42.3 | Upgrade |
Total Debt Repaid | -5.3 | -33.6 | -44.9 | -85.5 | -47 | -42.3 | Upgrade |
Net Debt Issued (Repaid) | -5.3 | -33.6 | -44.9 | -85.5 | -18.7 | -29 | Upgrade |
Issuance of Common Stock | 108 | 114.6 | 134.6 | 186.3 | 102 | 264.9 | Upgrade |
Repurchase of Common Stock | -2,682 | -1,582 | -653.7 | -172 | -1,561 | -739.4 | Upgrade |
Other Financing Activities | 3.5 | 6.2 | 1.8 | 3.5 | - | -1.8 | Upgrade |
Financing Cash Flow | -2,575 | -1,495 | -562.2 | -67.7 | -1,478 | -505.3 | Upgrade |
Foreign Exchange Rate Adjustments | 36.3 | -42.6 | 26.9 | -29.2 | -13.4 | 20.6 | Upgrade |
Net Cash Flow | -300.3 | -5,800 | -139.7 | 3,712 | 811.2 | 2,868 | Upgrade |
Free Cash Flow | 3,337 | -790.3 | 3,337 | 3,925 | 2,409 | 2,994 | Upgrade |
Free Cash Flow Growth | - | - | -14.99% | 62.97% | -19.55% | 100.39% | Upgrade |
Free Cash Flow Margin | 28.47% | -7.17% | 33.81% | 43.95% | 31.80% | 48.24% | Upgrade |
Free Cash Flow Per Share | 12.92 | -3.06 | 12.81 | 15.15 | 9.27 | 11.37 | Upgrade |
Cash Interest Paid | 12.1 | 30.5 | 43.1 | 52.3 | 56.3 | 54.5 | Upgrade |
Cash Income Tax Paid | 1,449 | 1,082 | 1,677 | 1,058 | 476.3 | 191.8 | Upgrade |
Levered Free Cash Flow | 2,914 | 2,800 | 3,510 | 3,307 | 2,402 | 2,232 | Upgrade |
Unlevered Free Cash Flow | 2,922 | 2,819 | 3,538 | 3,342 | 2,441 | 2,268 | Upgrade |
Change in Working Capital | -811.5 | -514.8 | -265.7 | 340.8 | -105.2 | -54.4 | Upgrade |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.